Breast Cancer

  1. BRCA 1&2 Mutation Test
    1. Indication: hereditary breast ovarian cancer
    2. Function: asses the risk of hereditary breast ovarian cancer
    3. Sample: 10 cc whole blood EDTA in cold storage and must be receipt not more than 36 hours by KalGen at working days since phlebotomy
    4. Analyte: whole DNA
    5. Method: next gene sequencing
    6. Interpretation: mutation is likely hereditary breast ovarian cancer
    7. TAT: 6 weeks
    8. Guideline: NCCN 2.2015 and ESMO

      This slideshow requires JavaScript.



  2. MammaPrint
    1. Indication: early stage breast cancer
    2. Function: asses prognosis value and risk level of early stage breast cancer
    3. Sample: histopathology (must be resection) fixed by neutral buffer formalin 10% in cell block with as much as tumor cells
    4. Analyte: 70 genes
    5. Method: micro-array
    6. Interpretation: low risk or high risk
    7. TAT: 1 month
    8. Guideline: ESMO

  3. ER PR HER2 Expression Test
    1. Indication: breast cancer
    2. Function: predict the effectivity of hormone therapy (tamoxifen) and anti human epidermal growth factor receptor 2/ HER2 (trastuzumab)
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells
    4. Analyte: protein
    5. Method: immunohistochemistry
    6. Interpretation: expression of ER or PR is eligible for hormone therapy and over expression (+3) is eligible for anti HER2 therapy
    7. TAT: 7 working days
    8. Guideline: NCCN 3.2015 and ESMO

  4. p53, Ki67, Topo2α, CathepsinD Expression Test (additional marker)
    1. Indication: breast cancer
    2. Function: asses prognosis value of breast cancer
    3. Sample: histopathology (resection or biopsy) fixed by neutral buffer formalin 10% in cell block or unstained coated slide with more than 200 tumor cells and contained more than 50% tumor cells
    4. Analyte: protein
    5. Method: immunohistochemistry
    6. Interpretation: p53 expression (> 50%) is bad prognosis, Ki67 expression is bad prognosis (> 14%), Topo2α expression (> 20%) is eligible for anthracycline therapy, CathepsinD expression is bad prognosis
    7. TAT: 7 working days
Advertisements